Undifferentiated Embryonal Sarcoma of the Liver
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- 入组人数
- 30
- 试验地点
- 1
- 主要终点
- Describe the relapse profile of children with undifferentiated hepatic sarcoma according to the therapies received
研究概览
简要总结
Undifferentiated embryonal sarcoma of the liver is the 3rd most common malignant liver tumor after hepatoblastoma and hepatocellular carcinoma with a peak incidence between 6 and 10 years of age. Historically, it is a tumor treated only by surgery with a poor prognosis. In the last decade, the combination of more intensive chemotherapy and, more randomly, radiotherapy, has significantly improved the survival rate of these patients. Due to its low incidence, there are few series reported in the literature and to date there is no specific treatment protocol for the management of these tumors.
It seems appropriate to review the management of these tumors in France in order to discuss the best therapeutic strategy.
研究设计
- 研究类型
- Observational
- 观察模型
- Case Only
- 时间视角
- Retrospective
入排标准
- 年龄范围
- 1 Year 至 25 Years（Child, Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- 未提供
排除标准
- 未提供
结局指标
主要结局
Describe the relapse profile of children with undifferentiated hepatic sarcoma according to the therapies received
时间窗: 3 years after treatment
the primary endpoint is event-free survival (progression, death, relapse) at 3 years.
次要结局
未报告次要终点